Your browser doesn't support javascript.
loading
Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients.
Wieme, Greet; Kral, Jan; Rosseel, Toon; Zemankova, Petra; Parton, Bram; Vocka, Michal; Van Heetvelde, Mattias; Kleiblova, Petra; Blaumeiser, Bettina; Soukupova, Jana; van den Ende, Jenneke; Nehasil, Petr; Tejpar, Sabine; Borecka, Marianna; Gómez García, Encarna B; Blok, Marinus J; Safarikova, Marketa; Kalousova, Marta; Geboes, Karen; De Putter, Robin; Poppe, Bruce; De Leeneer, Kim; Kleibl, Zdenek; Janatova, Marketa; Claes, Kathleen B M.
Afiliación
  • Wieme G; Center for Medical Genetics, Ghent University and Ghent University Hospital, 9000 Ghent, Belgium.
  • Kral J; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.
  • Rosseel T; Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic.
  • Zemankova P; Center for Medical Genetics, Ghent University and Ghent University Hospital, 9000 Ghent, Belgium.
  • Parton B; Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic.
  • Vocka M; Center for Medical Genetics, Ghent University and Ghent University Hospital, 9000 Ghent, Belgium.
  • Van Heetvelde M; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.
  • Kleiblova P; Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic.
  • Blaumeiser B; Center for Medical Genetics, Ghent University and Ghent University Hospital, 9000 Ghent, Belgium.
  • Soukupova J; Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.
  • van den Ende J; Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic.
  • Nehasil P; Center of Medical Genetics UZA/UA, Antwerp University Hospital, 2000 Antwerp, Belgium.
  • Tejpar S; Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic.
  • Borecka M; Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic.
  • Gómez García EB; Center of Medical Genetics UZA/UA, Antwerp University Hospital, 2000 Antwerp, Belgium.
  • Blok MJ; Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic.
  • Safarikova M; Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic.
  • Kalousova M; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic.
  • Geboes K; Digestive Oncology Unit, University Hospital Gasthuisberg, 3000 Leuven, Belgium.
  • De Putter R; Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic.
  • Poppe B; Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic.
  • De Leeneer K; Department of Clinical Genetics, Maastricht University Medical Centre, 6229 GR Maastricht, The Netherlands.
  • Kleibl Z; GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands.
  • Janatova M; Department of Clinical Genetics, Maastricht University Medical Centre, 6229 GR Maastricht, The Netherlands.
  • Claes KBM; GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands.
Cancers (Basel) ; 13(17)2021 Sep 02.
Article en En | MEDLINE | ID: mdl-34503238
ABSTRACT
(1)

Background:

The proportion and spectrum of germline pathogenic variants (PV) associated with an increased risk for pancreatic ductal adenocarcinoma (PDAC) varies among populations. (2)

Methods:

We analyzed 72 Belgian and 226 Czech PDAC patients by multigene panel testing. The prevalence of pathogenic variants (PV) in relation to personal/family cancer history were evaluated. PDAC risks were calculated using both gnomAD-NFE and population-matched controls. (3)

Results:

In 35/298 (11.7%) patients a PV in an established PDAC-predisposition gene was found. BRCA1/2 PV conferred a high risk in both populations, ATM and Lynch genes only in the Belgian subgroup. PV in other known PDAC-predisposition genes were rarer. Interestingly, a high frequency of CHEK2 PV was observed in both patient populations. PV in PDAC-predisposition genes were more frequent in patients with (i) multiple primary cancers (12/38; 32%), (ii) relatives with PDAC (15/56; 27%), (iii) relatives with breast/ovarian/colorectal cancer or melanoma (15/86; 17%) but more rare in sporadic PDAC (5/149; 3.4%). PV in homologous recombination genes were associated with improved overall survival (HR = 0.51; 95% CI 0.34-0.77). (4)

Conclusions:

Our analysis emphasizes the value of multigene panel testing in PDAC patients, especially in individuals with a positive family cancer history, and underlines the importance of population-matched controls for risk assessment.
Palabras clave

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Prevalence_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Bélgica

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Prevalence_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Bélgica